November 30th 2023
Here are some updates from the world of psychiatry throughout the month of November.
November 17th 2023
What is new in research on psychedelics?
November 11th 2023
From neurological abnormalities in first-episode psychosis to psychiatric boarding in emergency departments, here are highlights from the week in Psychiatric Times.
November 10th 2023
What is new in research on dementia?
November 6th 2023
New positive data for brexpiprazole, the first and only treatment approved to treat agitation associated with dementia due to Alzheimer disease.
Sleep Research Roundup: September 29
What is new in research on sleep?
World Alzheimer's Day 2023
Today is World Alzheimer's Day!
The Week in Review: July 17-21
From a look at adolescent substance use to special challenges in treating borderline personality disorder during the perinatal period, here are highlights from the week in Psychiatric Times.
Study Supports Neuroprotective, Disease-Modifying Effects of Clinical Drug Candidate in the Treatment of Alzheimer Disease
“The described effects of ACD856 may improve cognition, increase resilience, and promote neurorestorative processes, thereby leading to a healthier brain in patients with [Alzheimer disease].”
Experimental Drug Slows Progression of Alzheimer Disease in Patients With Mild Impairment by 60%
Trial results underscore the importance of early diagnosis and treatment in patients with Alzheimer disease.
The Week in Review: July 3-7
From the FDA traditional approval of Leqembi to an examination of how we can improve mental health care for women of color, here are highlights from the week in Psychiatric Times.
FDA Grants Traditional Approval to Leqembi for the Treatment of Alzheimer Disease
Announcement follows the FDA’s accelerated approval and unanimous endorsement of the drug earlier this year.
The Week in Review: May 8-12
From the relationship between social media and self-diagnosis to the FDA approval of the first treatment for agitation associated with Alzheimer disease dementia, here are highlights from the week in Psychiatric Times.
FDA Approves First Treatment for Agitation Associated With Alzheimer Disease Dementia
Brexpiprazole has been approved by the US Food and Drug Administration for the treatment of agitation associated with Alzheimer disease dementia.
The Week in Review: April 17-21
From eating disorders in entertainment to early intervention for schizophrenia, here are highlights from the week in Psychiatric Times.
Progress Made Toward the Approval of Treatment of Agitation Associated With Alzheimer Dementia
If approved, the drug will be the first FDA-approved treatment for agitation associated with Alzheimer dementia in the United States.
From the Pages of Psychiatric Times: March 2023
The experts weighed in on a wide variety of psychiatric issues for the March 2023 issue of Psychiatric Times.
The Week in Review: March 6-10
From Alzheimer disease treatments to the psychiatric implications of conspiracy theories, here are highlights from the week in Psychiatric Times.
The Clock-Drawing Test
A look at one of the most informative yet easy-to-administer tests for assessing brain dysfunction.
Lithium: A Narrative Overview and Future Frontiers
Lithium: what’s its history and where do we still need more information?
Alzheimer Disease: Are the Treatments Worse Than the Illness?
What are the available and upcoming AD treatments and how can you utilize them to best serve your patients?
From the Pages of Psychiatric Times: January 2023
The experts weighed in on a wide variety of psychiatric issues for the January 2023 issue of Psychiatric Times.
Is Alzheimer Disease Research Key to Effective Treatment of CTE in Athletes?
Alzheimer disease research may offer the key to effective treatment for former athletes.
The Week in Review: November 28-December 2
From evidence-based novel therapies for bipolar depression to potential indicators of early-stage Alzheimer disease, here are highlights from the week in Psychiatric Times.
Formic Acid as a Urinary Biomarker for Early-Stage Alzheimer Disease
New research finds that a urine test for formic acid could detect early-stage Alzheimer disease.
The Week in Review: November 7-11
From the cross-cultural dimensions of psychosis to the economic burden of schizophrenia, here are highlights from the week in Psychiatric Times.
Study Identifies Promising Potential Treatment for Alzheimer Disease
Results show comparisons between intranasal and intracerebroventricular distribution of an oxytocin derivative.
Treating Chronic Traumatic Encephalopathy in Athletes
Can Alzheimer disease research offer the key to effective treatment?
Caution Ahead: FDA Asks for More Info on Expanded Use of Antipsychotic Drug
Alzheimer disease psychosis treatment pimavanserin receives Complete Response Letter from the FDA.
Buyers Beware in Alzheimer Disease Neuroscience
Is our research about Alzheimer disease wrong?
Brain Inflammation May Link Alzheimer Disease With Sleep Disturbance
Study shows promising results for early detection and prevention efforts.
Phase 3 Study on Treatment of Agitation in Alzheimer Disease Doses First Patient
Top-line data for study is expected in late 2022, early 2023.
In Love: A Memoir of Love and Loss
Compelling new book discusses love, Alzheimer disease, and medical aid in dying.
Predicting Depression and Alzheimer Disease Through Major Depressive Disorder Risk Factors
Individuals with depression may be at a greater risk to develop late-onset Alzheimer disease, but a new study suggests depression onset may help predict Alzheimer disease.
The Science, Ethics, and Art of Disclosing a Dementia Diagnosis
How can you communicate the diagnosis in a way that relieves suffering and helps patients and their caregivers prepare for the future?
2 Clarke Drive Cranbury, NJ 08512